Kite and BBG Advanced Therapies Launch Mobile Leukapheresis Center in Texas to Enhance CAR T-Cell Therapy Patient Access and Streamline Supply Chain

July 19, 2026

Cellgenetherapyreview.com USA

Overview

Kite and BBG Advanced Therapies announced on July 9, 2026, the launch of a mobile leukapheresis center in Texas. This innovative initiative aims to significantly improve access to the apheresis process for CAR T-cell therapy patients. The Texas deployment will serve as a proof-of-concept model for potential additional implementations in other markets, substantially contributing to the streamlining of the CAR T-cell therapy manufacturing supply chain and enhancing the patient experience. This move is expected to alleviate geographical barriers, providing more patients with the opportunity to receive treatment.

In Depth

Key Findings

On July 9, 2026, Kite, a global leader in CAR T-cell therapy, announced a partnership with BBG Advanced Therapies to launch a mobile leukapheresis center in Texas. This groundbreaking initiative is specifically designed to significantly improve patient access to the critical apheresis process required for CAR T-cell therapy.

Technical / Clinical Details

CAR T-cell therapy involves a complex process: harvesting a patient’s own T-cells (apheresis), genetic modification ex vivo, cell expansion, and reinfusion. The initial step, leukapheresis, requires specialized equipment and trained medical staff, necessitating patients to travel to specific medical centers. The mobile apheresis center is a state-of-the-art specialized vehicle equipped with advanced apheresis machines, which will travel directly to patients’ homes or local healthcare facilities to collect the necessary white blood cells. This significantly reduces the patient’s travel burden and drastically improves geographical access to treatment. The deployment in Texas is positioned as a Proof-of-Concept model for future similar service expansions in other regions and countries. This system also holds the potential to simplify the overall CAR T-cell therapy supply chain and reduce manufacturing lead times.

Background & Context

While CAR T-cell therapy offers dramatic therapeutic effects for certain hematologic cancers, its high cost and complex logistical and manufacturing processes pose significant barriers to widespread adoption. The limited availability of apheresis facilities, in particular, has restricted where and when patients can receive treatment, impeding equitable access. The introduction of mobile centers is an innovative solution to address this supply chain bottleneck and deliver CAR T-cell therapy to a greater number of patients. The collaboration between Kite and BBG Advanced Therapies highlights that major pharmaceutical companies are actively investing in improving logistics and patient experience, signaling a transformative shift in standards across the cell therapy industry.

Strategic Significance & Outlook

The success of the mobile leukapheresis center in Texas will significantly impact patient access and supply chain efficiency in CAR T-cell therapy. If this model proves effective, national and international expansion is anticipated, potentially allowing more patients to access this innovative therapy without geographical or economic constraints. Furthermore, this concept could be applied to the delivery models of other advanced cell and gene therapies, accelerating the transformation of the broader regenerative medicine infrastructure. Through this initiative, Kite aims to further strengthen its patient-centric treatment approach.

Source: #

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.